Jim Cramer reviewed Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. When a caller asked about the stock during the lightning round, Cramer said:

Okay, I think we, I have to tell you, I think that this company is real. It’s doing better than people realize. It is speculative. I bless it. I bless it as a spec. You can get one spec, as we say in How to Make Money in Any Market. You can get one spec, and that’s the spec that I would buy for you.

A stock market data. Photo by AlphaTradeZone on Pexels

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechnology company that creates therapies to help patients with hematologic disorders and cancer. The company offers treatments for conditions such as immune thrombocytopenia and acute myeloid leukemia and is also developing new inhibitors for autoimmune and inflammatory diseases.

While we acknowledge the potential of RIGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.